Tirzepatide

What is Tirzepatide?

A dual-action peptide targeting both GIP and GLP-1 receptors. Shows even greater weight loss potential than semaglutide in head-to-head trials.

Tirzepatide represents the next generation of metabolic peptides by acting on two incretin receptors simultaneously. Clinical trials have demonstrated average weight reductions of up to 22.5% of body weight, making it the most effective weight loss peptide currently available.

Benefits & evidence

How it works

Unlike semaglutide which only targets GLP-1 receptors, tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual action enhances insulin sensitivity, reduces appetite through complementary pathways, and may also improve fat metabolism more effectively than targeting either receptor alone.

Dosing information

Side effects

Most side effects tend to improve as your body adjusts.

Research (186 studies)